Acer Therapeutics (ACER) and its collaboration partner, Relief (RLFTF) announced that the FDA has approved Olpruva for oral suspension in the U.S. for the treatment of certain patients living with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, or CPS, ornithine transcarbamylase, or OTC, or argininosuccinic acid synthetase, or AS.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACER:
- Acer Therapeutics Plunges Despite FDA Win
- Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
- Acer Therapeutics receives FDA approval for NDA for Olpruva
- 2 Biotech Stocks Under $10 That Could Win From Key FDA Approvals
- Fly Insider: Vapotherm, Applovin among week’s notable insider trades